Jazz Pharmaceuticals
JAZZ
Jazz Pharmaceuticals (JAZZ) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $5.71
- EPS estimate
- $6.18
- EPS surprise
- −7.53%
- Revenue surprise
- +8.42%
- Revenue
- $1.2B
- Revenue estimate
- $1.1B
- Reported
- Aug 3, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $6.18 | $5.71 | −7.53% | $1.2B | SEC |
| Q1 2026 | May 5, 2026 | $4.66 | $6.34 | +36.17% | $1.1B | SEC |
| Q4 2025 | Feb 24, 2026 | $6.52 | $6.64 | +1.88% | $1.2B | SEC |
| Q3 2025 | Nov 5, 2025 | $5.95 | $8.13 | +36.72% | $1.1B | SEC |
| Q2 2025 | Aug 5, 2025 | −$7.61 | −$8.25 | −8.47% | $1.0B | SEC |
| Q1 2025 | May 6, 2025 | $4.66 | $1.68 | −63.93% | $897.8M | SEC |
| Q4 2024 | Feb 25, 2025 | $5.86 | $6.60 | +12.60% | $1.1B | SEC |
| Q3 2024 | Nov 6, 2024 | $5.50 | $6.61 | +20.22% | $1.1B | SEC |
| Q2 2024 | Jul 31, 2024 | $4.92 | $5.30 | +7.68% | $1.0B | SEC |
| Q1 2024 | May 1, 2024 | $4.18 | $2.68 | −35.87% | $902.0M | SEC |
| Q4 2023 | Feb 28, 2024 | $5.18 | $5.02 | −3.18% | $1.0B | SEC |
| Q3 2023 | Nov 8, 2023 | $4.93 | $4.84 | −1.88% | $972.1M | SEC |
| Q2 2023 | Aug 9, 2023 | $4.45 | $4.51 | +1.45% | $957.3M | SEC |
| Q1 2023 | May 10, 2023 | $4.24 | $3.95 | −6.83% | $892.8M | SEC |
| Q4 2022 | Mar 1, 2023 | $0.88 | −$0.07 | −107.93% | $972.1M | SEC |
| Q3 2022 | Nov 9, 2022 | $4.66 | $5.17 | +10.93% | $940.7M | SEC |
| Q2 2022 | Aug 3, 2022 | $4.18 | $4.30 | +2.91% | $932.9M | SEC |
| Q1 2022 | May 4, 2022 | $3.84 | $3.73 | −2.86% | $813.7M | SEC |
| Q4 2021 | Mar 1, 2022 | $3.63 | $4.21 | +15.95% | $896.7M | SEC |
| Q3 2021 | Nov 9, 2021 | $3.32 | $4.20 | +26.56% | $838.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Jazz Pharmaceuticals (JAZZ) last report earnings?
Jazz Pharmaceuticals last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did JAZZ beat earnings estimates?
No. Jazz Pharmaceuticals reported EPS of $5.71 for Q2 2026 against a $6.18 estimate — a 7.53% miss.
How much revenue did JAZZ report last quarter?
Jazz Pharmaceuticals reported $1.2B in revenue for Q2 2026, against a consensus estimate of $1.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.